Meta-analysis of 6 RCTs (3,485 patients) in BCG-naive NMIBC: adding systemic ICIs to BCG reduced recurrence-related events (HR 0.77) but increased grade 3+ treatment-related adverse events (RR 3.97); BCG modifications did not help.
Meta-analysisn = 3,485
Roessler et al. First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysis